Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search

Haematolymphoid Tumours (5th ed.)

editHAEM5 Conversion Notes
This page was converted to the new template on 2023-12-07. The original page can be found at HAEM4:Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1.

(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use HUGO-approved gene names and symbols (italicized when appropriate), HGVS-based nomenclature for variants, as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see Author_Instructions and FAQs as well as contact your Associate Editor or Technical Support)

Primary Author(s)*

Christine Bryke, MD
Beth Israel Deaconess Medical Center, Boston, MA

Cancer Category / Type

Acute myeloid leukemia

Cancer Sub-Classification / Subtype

Acute myeloid leukaemia (AML) with t(8;21)(q22;q22.1) resulting in RUNX1-RUNX1T1 fusion

Definition / Description of Disease

Acute myeloid leukemia (AML) with t(8;21)(q22;q22) resulting in RUNX1-RUNX1T1 gene fusion defines a subtype of AML with neutrophil lineage maturation. In the 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia, it is in the group of AML with recurrent genetic abnormalities[1]. In the older French-American-British (FAB) classification system, t(8;21)(q22;q22) positive AML belonged to the acute myeloblastic leukemia with maturation M2 category and accounted for 10% of cases. t(8;21)(q22;q22) can occasionally be seen in therapy-related AML. In those instances the leukemia is not classified in the group of AML with recurrent genetic abnormalities due to clinical and prognostic differences. AML with t(8;21)(q22;q22) is a core binding leukemia (see Genes and Main Pathways Involved section below)[2].

  • t(8;21)(q22;q22) is a translocation involving the long arms of chromosomes 8 and 21 that defines a distinctive cytogenetic subtype of acute myeloid leukemia.
  • Complex translocations involving chromosomes 8, 21 and a third chromosome occur; the derivative chromosome 8 in the t(8;21)(q22;q22) and the variant t(8;21;var) carries the RUNX1-RUNX1T1 gene rearrangement.
  • Cases with cryptic RUNX1-RUNX1T1 gene rearrangement have been reported.
  • Note: The RUNX1T1 gene is currently located at 8q21.3. This gene was previously located at 8q22, which explains the discrepancy in the breakpoint given in the name for this WHO-defined disease entity.

Karyogram showing t(8;21)(q22;q22) translocation. Jennifer Otani, Beth Israel Deaconess Medical Center, Boston, MA
FISH RUNX1-RUNX1T1 probe set on metaphase cell with t(8;21)(q22;q22) translocation. Jennifer Otani, Beth Israel Deaconess Medical Center, Boston, MA.

Synonyms / Terminology


Epidemiology / Prevalence

Approximately 1-5% of AML cases have the t(8;21)(q22;q22.1)

  • Occurs mainly in younger patients
  • Mean age is 30 years
  • Most common type of AML in children

Clinical Features

Put your text here and fill in the table (Instruction: Can include references in the table)

Signs and Symptoms EXAMPLE Asymptomatic (incidental finding on complete blood counts)

EXAMPLE B-symptoms (weight loss, fever, night sweats)


EXAMPLE Lymphadenopathy (uncommon)

Laboratory Findings EXAMPLE Cytopenias

EXAMPLE Lymphocytosis (low level)

editv4:Clinical Features
The content below was from the old template. Please incorporate above.
  • May present as a myeloid sarcoma and, if so, the bone marrow aspirate blast count may be misleadingly low
  • Concurrent systemic mastocytosis has been reported.

Sites of Involvement

Bone marrow

Morphologic Features

  • Large blasts with abundant basophilic cytoplasm often with azurophilic granules and perinuclear clearing
  • Long sharp Auer rods are frequently observed.

Bone marrow aspirate with t(8;21)(q22;q22) blast with Auer rod (100X). Robert Willim, MD, Beth Israel Deaconess Medical Center, Boston, MA

  • Promyelocytes, myelocytes and metamyelocytes may have abnormal nuclear segmentation and cytoplasmic staining.
  • Normal eosinophil precursors are frequently increased and do not show the nuclear and cytoplasmic abnormalities seen in AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22).
  • Cases with t(8;21)(q22;q22.1) and less than 20% blast percentage in the marrow should be classified as AML rather than myelodysplastic syndrome according to the WHO 2017[3].


  • Blasts express CD34, HLA-DR, MPO, CD13, CD33 (weak), CD15 and/or CD65, co-expression of CD34. Lymphoid markers: CD19, PAX5, sometimes cytoplasmic CD79a
  • Occasional weak TdT positivity and/or CD56 expression may have adverse prognosis
Finding Marker
Positive (universal) CD34, HLA-DR, MPO, CD13, CD33 (weak), TdT (weak), CD56 (fraction of cases)
Positive (subset) CD15 and/or CD65
Positive (Lymphoid markers) CD19, PAX5, sometimes cytoplasmic CD79a
Negative (universal)
Negative (subset)

Chromosomal Rearrangements (Gene Fusions)

Put your text here and fill in the table

Chromosomal Rearrangement Genes in Fusion (5’ or 3’ Segments) Pathogenic Derivative Prevalence Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE t(9;22)(q34;q11.2) EXAMPLE 3'ABL1 / 5'BCR EXAMPLE der(22) EXAMPLE 20% (COSMIC)

EXAMPLE 30% (add reference)


The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).

editv4:Chromosomal Rearrangements (Gene Fusions)
The content below was from the old template. Please incorporate above.
Chromosomal Rearrangement Genes in Fusion (5’ or 3’ Segments) Pathogenic Derivative Prevalence
t(8;21)(q22;q22.1) 5' RUNX1 / 3'RUNX1T1 der(8) 1- 5% of AML

editv4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).
Please incorporate this section into the relevant tables found in:
  • Chromosomal Rearrangements (Gene Fusions)
  • Individual Region Genomic Gain/Loss/LOH
  • Characteristic Chromosomal Patterns
  • Gene Mutations (SNV/INDEL)


  • The presence of t(8;21)(q22;q22) is diagnostic of a cytogenetic subtype of acute myeloid leukemia with maturation in the neutrophilic lineage.
  • When t(8;21)(q22;q22) is present the diagnosis of acute myeloid leukemia is made regardless of a blast count less than 20%.


  • t(8;21)(q22;q22) positive AML usually has a good response to chemotherapy and a high complete remission rate with long-term disease-free survival when treated with high dose cytarabine in the consolidation phase. Factors that appear to adversely affected prognosis include CD56 expression and KIT gene mutations. The prognostic significance of other accompanying gene mutations is under investigation.

Therapeutic target:

  • t(8;21)(q22;q22) positive AML currently has no molecular target for drug therapy.
  • Standard induction 7 + 3 chemotherapy regimen of cytarabine for 7 days plus an anthracycline or anthracenedione for 3 days. In first complete remission patients younger than 60 years without a KIT mutation are treated with high dose cytarabine consolidation therapy. If a KIT mutation is present, bone marrow transplant is performed in first complete remission[4].
  • Recently homoharringtonine, aclarubicin and cytarabine as the first course of induction therapy has been found to be highly effective for acute myeloid leukemia with t(8;21)(q22;q22)[5].

Individual Region Genomic Gain / Loss / LOH

Put your text here and fill in the table (Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.)

Chr # Gain / Loss / Amp / LOH Minimal Region Genomic Coordinates [Genome Build] Minimal Region Cytoband Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes



chr7:1- 159,335,973 [hg38]




Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference).  Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference).




chr8:1-145,138,636 [hg38]




Common recurrent secondary finding for t(8;21) (add reference).

editv4:Genomic Gain/Loss/LOH
The content below was from the old template. Please incorporate above.

9q22 loss

Characteristic Chromosomal Patterns

Put your text here (EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis)

Chromosomal Pattern Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes

Co-deletion of 1p and 18q


See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).

editv4:Characteristic Chromosomal Aberrations / Patterns
The content below was from the old template. Please incorporate above.

Additional aberrations in >70% of cases with t(8;21); common loss of a sex chromosome or deletion 9q

Gene Mutations (SNV / INDEL)

Put your text here and fill in the table (Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.)

Gene; Genetic Alteration Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other) Prevalence (COSMIC / TCGA / Other) Concomitant Mutations Mutually Exclusive Mutations Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE: TP53; Variable LOF mutations


EGFR; Exon 20 mutations

EXAMPLE: BRAF; Activating mutations


EXAMPLE: 30% (add Reference)

EXAMPLE: IDH1 R123H EXAMPLE: EGFR amplification EXAMPLE:  Excludes hairy cell leukemia (HCL) (add reference).

Note: A more extensive list of mutations can be found in cBioportal (, COSMIC (, ICGC ( and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.

editv4:Gene Mutations (SNV/INDEL)
The content below was from the old template. Please incorporate above.

AML with t(8;21)(q22;q22) has genetic heterogeneity at the molecular level. Several genes have been identified that are frequently mutated in this subset of AML, some of them adversely affecting prognosis.

  • KIT mutations occur in 20-25% of cases and are associated with a high risk of relapse in AML with t(8;21)(q22;q22)[6]. Patients with KIT mutations have a significantly shorter overall survival and disease free survival periods than those without KIT mutations[7].
  • In a study of 139 t(8;21)(q22;q22) AML patients were investigated for possible mutations in KIT and 10 other genes (ASXL1, FLT3, NPM1, MLL, IDH1, IDH2, KRAS, NRAS, CBL, and JAK2)[5]. 49.6% had one mutation in addition to the t(8;21)(q22;q22). These were most often KIT, NRAS and ASXL1. 16.5% of patients had ≥2 mutations. Infrequent accompanying mutated genes found in only 2.9-5% of cases include in decreasing frequency: FLT3-ITD, FLT3-TKD, CBL, and KRAS, IDH2 and JAK2. These mutations did not adversely affect prognosis. NPM1 mutations are thought to be mutually exclusive of RUNX1-RUNX1T1.
  • ASXL2 mutations have been identified in greater than 20% of patients with t(8;21), but not in patients with inv(16)/t(16;16) or RUNX1-mutated AML[8]. ASXL2 mutations are similarly frequent in adults and children with t(8;21) and are mutually exclusive with ASXL1 mutations. Although overall survival is similar between ASXL1 and ASXL2 mutant t(8;21) AML patients and their wild-type counterparts, patients with ASXL1 or ASXL2 mutations had a cumulative incidence of relapse that is significantly higher than with their ASXL1 or ASXL2 wild-type counterparts[8].
  • Recurring ZBTB7A mutations have been identified in 23% (13/56) of AML t(8;21) patients, including missense and truncating mutations resulting in alteration or loss of the C-terminal zinc-finger domain of ZBTB7A[9]. The transcription factor ZBTB7A is important for hematopoietic lineage fate decisions and for regulation of glycolysis. On a functional level, it has been shown that ZBTB7A mutations disrupt the transcriptional repressor potential and the anti-proliferative effect of ZBTB7A. The specific association of ZBTB7A mutations with t(8;21) rearranged AML points towards leukemogenic cooperativity between mutant ZBTB7A and the RUNX1/RUNX1T1 fusion[9].
  • WT1 mutations have been found to be relatively common (13.8%) in core binding factor leukemia[10]. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation[11].
Gene Mutation Oncogene/Tumor Suppressor/Other Presumed Mechanism (LOF/GOF/Other; Driver/Passenger) Prevalence (COSMIC/TCGA/Other)
KIT 20-30%

Other Mutations

Type Gene/Region/Other
Concomitant Mutations NRAS and ASXL1
Secondary Mutations
Mutually Exclusive ASXL1 and ASXL2

Epigenomic Alterations


Genes and Main Pathways Involved

Put your text here and fill in the table (Instructions: Can include references in the table.)

Gene; Genetic Alteration Pathway Pathophysiologic Outcome
EXAMPLE: BRAF and MAP2K1; Activating mutations EXAMPLE: MAPK signaling EXAMPLE: Increased cell growth and proliferation
EXAMPLE: CDKN2A; Inactivating mutations EXAMPLE: Cell cycle regulation EXAMPLE: Unregulated cell division
EXAMPLE:  KMT2C and ARID1A; Inactivating mutations EXAMPLE:  Histone modification, chromatin remodeling EXAMPLE:  Abnormal gene expression program
editv4:Genes and Main Pathways Involved
The content below was from the old template. Please incorporate above.


  • RUNX1T1 (also known as ETO) on 8q22 is transcribed from telomere to centromere; 3 proline rich domains; 2 zinc finger, and a PEST region in the C-terminus; tissue restricted expression; nuclear localization; putative transcription factor.
  • RUNX1 (also known as AML1 and CBFA) on 21q22; contains a runt domain and a transactivation domain in the C-terminus; forms heterodimers; widely expressed; nuclear localization; transcription factor (activator) for various hematopoietic-specific genes.


  • t(8;21)(q22;q22) results in a 5’RUNX1-3’RUNX1T1 hybrid gene involving fusion of the very 5’ end of the RUNX1T1 gene to RUNX1 in an ~25 kb breakpoint region between exons 5 and 6.


  • A fusion protein with the N-terminus runt domain (responsible for DNA binding and protein-protein interaction) of RUNX1 fused to the 577 C-terminal residues of RUNX1T1. The reciprocal product is not detected. The fusion protein retains the ability to recognize the RUNX1 consensus DNA binding site (it is a negative dominant competitor with the normal RUNX1) and to dimerize with the CBFβ subunit in the heterodimeric core binding factor. The core binding factor is a transcription factor that plays an essential role in regulation of normal hematopoiesis. It is composed of a DNA-binding CBFα (RUNX1) chain and a non-DNA-binding CBFβ chain. It is likely oncogenic due to altered transcriptional regulation of normal RUNX1 target genes. Animal studies suggest that the fusion proteins alone are not able to induce leukemia and that additional genetic alterations are required for leukemogenic transformation[12][13].

Key cellular pathways:

  • The normal transcriptional activity of the RUNX1 protein in the core binding factor is affected in a negative manner by the chimeric protein encoded by the RUNX1-RUNX1T1 fusion gene. It has been proposed that the RUNX1-RUNX1T1 protein recruits histone deacetylases and DNA methyl transferase 1 to core binding factor target genes[14]. This leads to increased chromatin deacetylation and promotor hypermethylation, resulting in gene transcriptional repression and disruption of normal cellular pathways of hematopoiesis.

Genetic Diagnostic Testing Methods

  • Chromosome analysis, FISH, RT-PCR
  • FISH or RT-PCR is needed for cytogenetically cryptic cases with typical blast morphology and immunophenotype
  • RT-PCR is employed for minimal residual disease detection

FISH with RUNX1-RUNX1T1 probe set on interphase cells with t(8;21)(q22;q22) translocation. Nancy Hsu and Min Zhang, Beth Israel Deaconess Medical Center, Boston, MA.

Familial Forms


Additional Information





KIT mutations in AML COSMIC database cytogenetics in AML RUNX1 RUNX1T1


(use the "Cite" icon at the top of the page) (Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference.)

  1. Arber, Daniel A.; et al. (2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): 2391–2405. doi:10.1182/blood-2016-03-643544. ISSN 1528-0020. PMID 27069254.
  2. Sangle, Nikhil A.; et al. (2011). "Core-binding factor acute myeloid leukemia". Archives of Pathology & Laboratory Medicine. 135 (11): 1504–1509. doi:10.5858/arpa.2010-0482-RS. ISSN 1543-2165. PMID 22032582.
  3. Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France.
  4. Tallman, Martin S.; et al. (2019-06-01). "Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology". Journal of the National Comprehensive Cancer Network: JNCCN. 17 (6): 721–749. doi:10.6004/jnccn.2019.0028. ISSN 1540-1413. PMID 31200351.
  5. 5.0 5.1 Krauth, M.-T.; et al. (2014). "High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome". Leukemia. 28 (7): 1449–1458. doi:10.1038/leu.2014.4. ISSN 1476-5551. PMID 24402164.
  6. Paschka, Peter; et al. (2006). "Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study". Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 24 (24): 3904–3911. doi:10.1200/JCO.2006.06.9500. ISSN 1527-7755. PMID 16921041.
  7. Kim, Hee-Jin; et al. (2013). "KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement". Annals of Hematology. 92 (2): 163–171. doi:10.1007/s00277-012-1580-5. ISSN 1432-0584. PMID 23053179.
  8. 8.0 8.1 Micol, Jean-Baptiste; et al. (2014). "Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations". Blood. 124 (9): 1445–1449. doi:10.1182/blood-2014-04-571018. ISSN 1528-0020. PMC 4148766. PMID 24973361.
  9. 9.0 9.1 Hartmann, Luise; et al. (2016). "ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation". Nature Communications. 7: 11733. doi:10.1038/ncomms11733. ISSN 2041-1723. PMC 4895769. PMID 27252013.
  10. Park, Sang Hyuk; et al. (2015). "Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population". Annals of Laboratory Medicine. 35 (3): 288–297. doi:10.3343/alm.2015.35.3.288. ISSN 2234-3814. PMC 4390696. PMID 25932436.
  11. Qin, Ya-Zhen; et al. (2016). "Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation". Chinese Journal of Cancer. 35: 46. doi:10.1186/s40880-016-0110-6. ISSN 1944-446X. PMC 4873994. PMID 27197573.
  12. Speck, Nancy A.; et al. (2002). "Core-binding factors in haematopoiesis and leukaemia". Nature Reviews. Cancer. 2 (7): 502–513. doi:10.1038/nrc840. ISSN 1474-175X. PMID 12094236.
  13. Downing, James R. (2003). "The core-binding factor leukemias: lessons learned from murine models". Current Opinion in Genetics & Development. 13 (1): 48–54. doi:10.1016/s0959-437x(02)00018-7. ISSN 0959-437X. PMID 12573435.
  14. Marcucci, Guido (2006). "Core binding factor acute myeloid leukemia". Clinical Advances in Hematology & Oncology: H&O. 4 (5): 339–341. ISSN 1543-0790. PMID 16728942.


*Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.

Edited by: Fabiola Quintero-Rivera 7/21/2018

*Citation of this Page: “Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated 12/13/2023,